Yuan C S, Foss J F
Department of Anesthesia and Critical Care, The Pritzker School of Medicine, The University of Chicago, IL 60637, USA.
Neuropharmacology. 1999 Mar;38(3):425-32. doi: 10.1016/s0028-3908(98)00192-0.
In this study, we evaluated the gastric effects of methylnaltrexone, an opioid receptor antagonist that does not cross the blood-brain barrier in vivo, on mu, kappa and delta opioid agonists induced brainstem unitary responses in an in vitro neonatal rat brainstem-gastric preparation. Single units in the medial subnucleus of the nucleus tractus solitarius (NTS), responding to electrical stimulation of subdiaphragmatic vagal fibers, were recorded. Selective opioid receptor agonists and antagonists were applied only to the gastric compartment of the bath chamber and thus, the brainstem functions of the preparation were not affected by the drugs. The peripheral gastric effects of a mu opioid receptor agonist, DAMGO, and a kappa opioid receptor agonist, U-50,488H, were evaluated on 58 tonic units that received the subdiaphragmatic vagal inputs. For approximately 78% of the units observed, DAMGO (1.0 microM) and U-50,488H (1.0 microM) induced a concentration-dependent inhibition of 62.1+/-9.3% (mean +/- SE) and 49.2+/-6.5% of the control level of the NTS neuronal activity, respectively. Methylnaltrexone competitively antagonized the DAMGO-induced brainstem neuronal effects. Methylnaltrexone at an 18.8-fold higher concentration also reversed U-50,488H-induced NTS neuronal responses. Naloxone, a non-selective opioid receptor antagonist, reversed the inhibitory effects of DAMGO and U-50,488H at much lower concentrations (3.8% and 0.5%, respectively) compared to methylnaltrexone. Only 18% of the NTS neurons evaluated showed inhibitory responses to a delta receptor agonist, DPDPE, (19.7+/-5.0% at 10 microM), and this inhibition could not be reversed by methylnaltrexone in the concentration range we tested. In addition, when methylnaltrexone (1.0 microM) alone was applied to the gastric compartment, there was an activation (8.5+/-2.1%) of the NTS neurons receiving subdiaphragmatic vagal inputs, suggesting an endogenous gastric opioid action in the modulation of brainstem neuronal activities.
在本研究中,我们评估了甲基纳曲酮对μ、κ和δ阿片受体激动剂诱导的体外新生大鼠脑干-胃标本中脑干单一反应的胃效应。甲基纳曲酮是一种体内不穿过血脑屏障的阿片受体拮抗剂。记录了孤束核(NTS)内侧亚核中对膈下迷走神经纤维电刺激有反应的单个单位。选择性阿片受体激动剂和拮抗剂仅应用于浴槽室的胃部分,因此,标本的脑干功能不受药物影响。在58个接受膈下迷走神经输入的紧张性单位上评估了μ阿片受体激动剂DAMGO和κ阿片受体激动剂U-50,488H的外周胃效应。在所观察的约78%的单位中,DAMGO(1.0微摩尔)和U-50,488H(1.0微摩尔)分别浓度浓度分别诱导NTS神经元活动对照水平浓度依赖性抑制62.1±9.3%和49.2±6.5%。甲基纳曲酮竞争性拮抗DAMGO诱导的脑干神经元效应。浓度高18.8倍的甲基纳曲酮也能逆转U-50,488H诱导的NTS神经元反应。与甲基纳曲酮相比,非选择性阿片受体拮抗剂纳洛酮在低得多的浓度(分别为3.8%和0.5%)下就能逆转DAMGO和U-50,488H的抑制作用。在所评估的NTS神经元中,只有18%对δ受体激动剂DPDPE(10微摩尔时为19.7±5.0%)表现出抑制反应,并且在我们测试的浓度范围内,这种抑制不能被甲基纳曲酮逆转。此外,当单独将甲基纳曲酮(1.0微摩尔)应用于胃部分时,接受膈下迷走神经输入的NTS神经元有激活(8.5±2.1%),提示内源性胃阿片在调节脑干神经元活动中有作用。